<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Media S.A. pmcid: 7419580 doi: 10.3389/fmed.2020.00420 : Medicine: Mini Review" exact="Secondary" post="Bacterial Infections in Patients With Viral Pneumonia ManoharPrasanth12LohBelinda1NachimuthuRamesh3HuaXiaoting45WelburnSusan C.16LeptihnSebastian146*[],"/>
 <result pre="S.A. pmcid: 7419580 doi: 10.3389/fmed.2020.00420 : Medicine: Mini Review Secondary" exact="Bacterial Infections" post="in Patients With Viral Pneumonia ManoharPrasanth12LohBelinda1NachimuthuRamesh3HuaXiaoting45WelburnSusan C.16LeptihnSebastian146*[], 1Zhejiang University-University"/>
 <result pre="pmcid: 7419580 doi: 10.3389/fmed.2020.00420 : Medicine: Mini Review Secondary Bacterial" exact="Infections" post="in Patients With Viral Pneumonia ManoharPrasanth12LohBelinda1NachimuthuRamesh3HuaXiaoting45WelburnSusan C.16LeptihnSebastian146*[], 1Zhejiang University-University"/>
 <result pre=": Medicine: Mini Review Secondary Bacterial Infections in Patients With" exact="Viral" post="Pneumonia ManoharPrasanth12LohBelinda1NachimuthuRamesh3HuaXiaoting45WelburnSusan C.16LeptihnSebastian146*[], 1Zhejiang University-University of Edinburgh (ZJU-UoE) Institute,"/>
 <result pre="Medicine: Mini Review Secondary Bacterial Infections in Patients With Viral" exact="Pneumonia" post="ManoharPrasanth12LohBelinda1NachimuthuRamesh3HuaXiaoting45WelburnSusan C.16LeptihnSebastian146*[], 1Zhejiang University-University of Edinburgh (ZJU-UoE) Institute, Zhejiang"/>
 <result pre="of Medicine, The Second Affiliated Hospital Zhejiang University (SAHZU)HangzhouChina[], 3Antibiotic" exact="Resistance" post="and Phage Therapy Laboratory, School of Bio Sciences and"/>
 <result pre="Sciences and Technology, Vellore Institute of Technology (VIT)VelloreIndia[], 4Department of" exact="Infectious" post="Diseases, Sir Run Run Shaw Hospital, Zhejiang University School"/>
 <result pre="Mexico *Correspondence: Sebastian Leptihn Leptihn@intl.zju.edu.cn This article was submitted to" exact="Infectious" post="Diseases - Surveillance, Prevention and Treatment, a section of"/>
 <result pre="*Correspondence: Sebastian Leptihn Leptihn@intl.zju.edu.cn This article was submitted to Infectious" exact="Diseases" post="- Surveillance, Prevention and Treatment, a section of the"/>
 <result pre="is permitted which does not comply with these terms. Abstract" exact="Pulmonary" post="diseases of viral origin are often followed by the"/>
 <result pre="does not comply with these terms. Abstract Pulmonary diseases of" exact="viral" post="origin are often followed by the manifestation of secondary"/>
 <result pre="of viral origin are often followed by the manifestation of" exact="secondary" post="infections, leading to further clinical complications and negative disease"/>
 <result pre="of secondary infections, leading to further clinical complications and negative" exact="disease" post="outcomes. Thus, research on secondary infections is essential. Here,"/>
 <result pre="further clinical complications and negative disease outcomes. Thus, research on" exact="secondary" post="infections is essential. Here, we review clinical data of"/>
 <result pre="clinical complications and negative disease outcomes. Thus, research on secondary" exact="infections" post="is essential. Here, we review clinical data of secondary"/>
 <result pre="secondary infections is essential. Here, we review clinical data of" exact="secondary" post="bacterial infections developed after the onset of pulmonary viral"/>
 <result pre="infections is essential. Here, we review clinical data of secondary" exact="bacterial infections" post="developed after the onset of pulmonary viral infections. We"/>
 <result pre="is essential. Here, we review clinical data of secondary bacterial" exact="infections" post="developed after the onset of pulmonary viral infections. We"/>
 <result pre="data of secondary bacterial infections developed after the onset of" exact="pulmonary" post="viral infections. We review the most recent clinical data"/>
 <result pre="of secondary bacterial infections developed after the onset of pulmonary" exact="viral" post="infections. We review the most recent clinical data and"/>
 <result pre="review the most recent clinical data and current knowledge of" exact="secondary" post="bacterial infections and their treatment in SARS-CoV-2 positive patients;"/>
 <result pre="the most recent clinical data and current knowledge of secondary" exact="bacterial infections" post="and their treatment in SARS-CoV-2 positive patients; case reports"/>
 <result pre="most recent clinical data and current knowledge of secondary bacterial" exact="infections" post="and their treatment in SARS-CoV-2 positive patients; case reports"/>
 <result pre="patients; case reports from SARS-CoV, MERS-CoV, SARS-CoV2 and the best-studied" exact="respiratory" post="virus, influenza, are described. We outline treatments used or"/>
 <result pre="described. We outline treatments used or prophylactic measures employed for" exact="secondary" post="bacterial infections. This evaluation includes recent clinical reports of"/>
 <result pre="We outline treatments used or prophylactic measures employed for secondary" exact="bacterial infections." post="This evaluation includes recent clinical reports of pulmonary viral"/>
 <result pre="secondary bacterial infections. This evaluation includes recent clinical reports of" exact="pulmonary" post="viral infections, including those by COVID-19, that reference secondary"/>
 <result pre="bacterial infections. This evaluation includes recent clinical reports of pulmonary" exact="viral" post="infections, including those by COVID-19, that reference secondary infections."/>
 <result pre="of pulmonary viral infections, including those by COVID-19, that reference" exact="secondary" post="infections. Where data was provided for COVID-19 patients, a"/>
 <result pre="for COVID-19 patients, a mortality rate of 15.2% due to" exact="secondary" post="bacterial infections was observed for patients with pneumonia (41"/>
 <result pre="COVID-19 patients, a mortality rate of 15.2% due to secondary" exact="bacterial infections" post="was observed for patients with pneumonia (41 of 268)."/>
 <result pre="patients, a mortality rate of 15.2% due to secondary bacterial" exact="infections" post="was observed for patients with pneumonia (41 of 268)."/>
 <result pre="due to secondary bacterial infections was observed for patients with" exact="pneumonia" post="(41 of 268). Most clinicians treated patients with SARS-CoV-2"/>
 <result pre="pneumonia (41 of 268). Most clinicians treated patients with SARS-CoV-2" exact="infections" post="with prophylactic antibiotics (63.7%, n = 1,901), compared to"/>
 <result pre="to 73.5% (n = 3,072) in all clinical reports of" exact="viral pneumonia" post="included in this review. For all cases of viral"/>
 <result pre="73.5% (n = 3,072) in all clinical reports of viral" exact="pneumonia" post="included in this review. For all cases of viral"/>
 <result pre="viral pneumonia included in this review. For all cases of" exact="viral pneumonia," post="a mortality rate of 10.9% due to secondary infections"/>
 <result pre="of viral pneumonia, a mortality rate of 10.9% due to" exact="secondary" post="infections was observed (53 of 482). Most commonly, quinolones,"/>
 <result pre="viral pneumonia, a mortality rate of 10.9% due to secondary" exact="infections" post="was observed (53 of 482). Most commonly, quinolones, cephalosporins"/>
 <result pre="and macrolides were administered, but also the glycopeptide vancomycin. Several" exact="bacterial" post="pathogens appear to be prevalent as causative agents of"/>
 <result pre="bacterial pathogens appear to be prevalent as causative agents of" exact="secondary" post="infections, including antibiotic-resistant strains of Staphylococcus aureus and Klebsiella"/>
 <result pre="infections, including antibiotic-resistant strains of Staphylococcus aureus and Klebsiella pneumoniae." exact="secondary" post="bacterial infection pulmonary viruses viral pneumonia SARS-CoV-2 COVID-19 influenza"/>
 <result pre="including antibiotic-resistant strains of Staphylococcus aureus and Klebsiella pneumoniae. secondary" exact="bacterial infection" post="pulmonary viruses viral pneumonia SARS-CoV-2 COVID-19 influenza SARS antibiotic"/>
 <result pre="antibiotic-resistant strains of Staphylococcus aureus and Klebsiella pneumoniae. secondary bacterial" exact="infection" post="pulmonary viruses viral pneumonia SARS-CoV-2 COVID-19 influenza SARS antibiotic"/>
 <result pre="strains of Staphylococcus aureus and Klebsiella pneumoniae. secondary bacterial infection" exact="pulmonary" post="viruses viral pneumonia SARS-CoV-2 COVID-19 influenza SARS antibiotic resistance"/>
 <result pre="Staphylococcus aureus and Klebsiella pneumoniae. secondary bacterial infection pulmonary viruses" exact="viral pneumonia" post="SARS-CoV-2 COVID-19 influenza SARS antibiotic resistance fig-count: table-count: equation-count:"/>
 <result pre="aureus and Klebsiella pneumoniae. secondary bacterial infection pulmonary viruses viral" exact="pneumonia" post="SARS-CoV-2 COVID-19 influenza SARS antibiotic resistance fig-count: table-count: equation-count:"/>
 <result pre="resistance fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Viruses causing" exact="respiratory" post="tract infections have been the cause of high morbidities"/>
 <result pre="table-count: equation-count: ref-count: page-count: word-count: Introduction Viruses causing respiratory tract" exact="infections" post="have been the cause of high morbidities and mortality"/>
 <result pre="20 years, the world has experienced six major outbreaks of" exact="infectious" post="agents (SARS-CoV: 2002-2004; H1N1 Influenza: 2009–2010; MERS-CoV: 2012–2020; Ebola"/>
 <result pre="MERS-CoV: 2012–2020; Ebola virus: 2013–2016; Zika virus: 2015–2016; SARS-CoV-2: 2019-present)," exact="infection" post="with four of which (SARS-CoV, H1N1 Influenza, MERS-CoV, SARS-CoV-2)"/>
 <result pre="virus: 2015–2016; SARS-CoV-2: 2019-present), infection with four of which (SARS-CoV," exact="H1N1 Influenza," post="MERS-CoV, SARS-CoV-2) result in respiratory tract infections. During the"/>
 <result pre="four of which (SARS-CoV, H1N1 Influenza, MERS-CoV, SARS-CoV-2) result in" exact="respiratory" post="tract infections. During the emergency of a viral disease,"/>
 <result pre="result in respiratory tract infections. During the emergency of a" exact="viral" post="disease, attention is initially focussed on clinical management of"/>
 <result pre="disease, attention is initially focussed on clinical management of the" exact="primary" post="infection, but it is imperative to consider secondary bacterial"/>
 <result pre="of the primary infection, but it is imperative to consider" exact="secondary" post="bacterial infections that develop in patients during or following"/>
 <result pre="the primary infection, but it is imperative to consider secondary" exact="bacterial infections" post="that develop in patients during or following initial infection."/>
 <result pre="primary infection, but it is imperative to consider secondary bacterial" exact="infections" post="that develop in patients during or following initial infection."/>
 <result pre="or following initial infection. In addition, co-infections - the simultaneous" exact="infection" post="with a second pathogen of viral or bacterial origin-"/>
 <result pre="co-infections - the simultaneous infection with a second pathogen of" exact="viral" post="or bacterial origin- can also occur and ultimately result"/>
 <result pre="the simultaneous infection with a second pathogen of viral or" exact="bacterial" post="origin- can also occur and ultimately result in the"/>
 <result pre="by two different pathogens (2, 3). One major complication of" exact="viral" post="infections, especially pulmonary viruses, is colonization of the viral"/>
 <result pre="pathogens (2, 3). One major complication of viral infections, especially" exact="pulmonary" post="viruses, is colonization of the viral affected organs by"/>
 <result pre="of viral infections, especially pulmonary viruses, is colonization of the" exact="viral" post="affected organs by bacteria which is associated with high"/>
 <result pre="immune response and/or opportunistic and accessible routes of entry for" exact="bacterial" post="pathogen(s) (4). While secondary bacterial infections or superinfections are"/>
 <result pre="and accessible routes of entry for bacterial pathogen(s) (4). While" exact="secondary" post="bacterial infections or superinfections are largely a consequence of"/>
 <result pre="accessible routes of entry for bacterial pathogen(s) (4). While secondary" exact="bacterial infections" post="or superinfections are largely a consequence of immune susceptibility"/>
 <result pre="routes of entry for bacterial pathogen(s) (4). While secondary bacterial" exact="infections" post="or superinfections are largely a consequence of immune susceptibility"/>
 <result pre="are largely a consequence of immune susceptibility caused by the" exact="primary" post="viral infection, co-infections are multiple infections (viral/bacterial/yeast) that occur"/>
 <result pre="largely a consequence of immune susceptibility caused by the primary" exact="viral infection," post="co-infections are multiple infections (viral/bacterial/yeast) that occur simultaneously. Co-infections,"/>
 <result pre="susceptibility caused by the primary viral infection, co-infections are multiple" exact="infections" post="(viral/bacterial/yeast) that occur simultaneously. Co-infections, secondary infections or &quot;superinfections&quot;"/>
 <result pre="infection, co-infections are multiple infections (viral/bacterial/yeast) that occur simultaneously. Co-infections," exact="secondary" post="infections or &quot;superinfections&quot; are common during viral pandemics. The"/>
 <result pre="co-infections are multiple infections (viral/bacterial/yeast) that occur simultaneously. Co-infections, secondary" exact="infections" post="or &quot;superinfections&quot; are common during viral pandemics. The 1918"/>
 <result pre="occur simultaneously. Co-infections, secondary infections or &quot;superinfections&quot; are common during" exact="viral" post="pandemics. The 1918 Spanish Flu pandemic saw around 50"/>
 <result pre="Spanish Flu pandemic saw around 50 million deaths ascribed to" exact="bacterial" post="co-infections and during the 2009 H1N1 Influenza pandemic up"/>
 <result pre="million deaths ascribed to bacterial co-infections and during the 2009" exact="H1N1 Influenza" post="pandemic up to 34% of all deaths were a"/>
 <result pre="up to 34% of all deaths were a result of" exact="bacterial" post="co-infections (5). These complications are often neglected in the"/>
 <result pre="clinical record (Figure 1B) (6, 7). Figure 1 (A) Possible" exact="disease" post="progression after infection with a respiratory virus. (B) Overview"/>
 <result pre="1B) (6, 7). Figure 1 (A) Possible disease progression after" exact="infection" post="with a respiratory virus. (B) Overview of case reports"/>
 <result pre="Figure 1 (A) Possible disease progression after infection with a" exact="respiratory" post="virus. (B) Overview of case reports of all respiratory"/>
 <result pre="a respiratory virus. (B) Overview of case reports of all" exact="respiratory" post="virus infection data reviewed in this study, including rate"/>
 <result pre="respiratory virus. (B) Overview of case reports of all respiratory" exact="virus infection" post="data reviewed in this study, including rate of secondary"/>
 <result pre="virus. (B) Overview of case reports of all respiratory virus" exact="infection" post="data reviewed in this study, including rate of secondary"/>
 <result pre="virus infection data reviewed in this study, including rate of" exact="secondary" post="bacterial infections, antibiotic use and pathogenic bacteria identified. While"/>
 <result pre="infection data reviewed in this study, including rate of secondary" exact="bacterial infections," post="antibiotic use and pathogenic bacteria identified. While the precise"/>
 <result pre="use and pathogenic bacteria identified. While the precise mechanism for" exact="susceptibility to" post="secondary infections is poorly understood, it is likely that"/>
 <result pre="pathogenic bacteria identified. While the precise mechanism for susceptibility to" exact="secondary" post="infections is poorly understood, it is likely that virus-mediated"/>
 <result pre="bacteria identified. While the precise mechanism for susceptibility to secondary" exact="infections" post="is poorly understood, it is likely that virus-mediated immunosuppression"/>
 <result pre="response to one pathogen may alter the immunity to other" exact="infectious" post="agent(s), resulting in increased prevalence of viral-induced secondary bacterial"/>
 <result pre="to other infectious agent(s), resulting in increased prevalence of viral-induced" exact="secondary" post="bacterial infections (10). Mammalian cells are more susceptible to"/>
 <result pre="other infectious agent(s), resulting in increased prevalence of viral-induced secondary" exact="bacterial infections" post="(10). Mammalian cells are more susceptible to bacterial attachment"/>
 <result pre="infectious agent(s), resulting in increased prevalence of viral-induced secondary bacterial" exact="infections" post="(10). Mammalian cells are more susceptible to bacterial attachment"/>
 <result pre="secondary bacterial infections (10). Mammalian cells are more susceptible to" exact="bacterial" post="attachment and colonization when infected by a virus (11,"/>
 <result pre="attachment and colonization when infected by a virus (11, 12);" exact="infection" post="with respiratory syncytial virus (RSV), rhinovirus and influenza virus"/>
 <result pre="colonization when infected by a virus (11, 12); infection with" exact="respiratory" post="syncytial virus (RSV), rhinovirus and influenza virus (all of"/>
 <result pre="virus (all of which damage the mucosal layer), lead to" exact="bacterial" post="adherence of Streptococcus pneumoniae, Pseudomonas aeruginosa, and Haemophilus influenzae,"/>
 <result pre="the linings of the airways (13). Common bacteria isolated during" exact="secondary" post="infections include Staphylococcus aureus, S. pneumoniae, Neisseria meningitides, H."/>
 <result pre="linings of the airways (13). Common bacteria isolated during secondary" exact="infections" post="include Staphylococcus aureus, S. pneumoniae, Neisseria meningitides, H. influenzae,"/>
 <result pre="of the Proteus, Enterobacter and Citrobacter spp. (14). During active" exact="viral" post="infections, the route of infection, proximity of infection as"/>
 <result pre="During active viral infections, the route of infection, proximity of" exact="infection" post="as well as virulence factors varies between bacterial strains"/>
 <result pre="proximity of infection as well as virulence factors varies between" exact="bacterial" post="strains resulting in different outcomes. Effective treatment of both"/>
 <result pre="strains resulting in different outcomes. Effective treatment of both the" exact="viral" post="and the secondary bacterial infection(s) is of critical importance."/>
 <result pre="different outcomes. Effective treatment of both the viral and the" exact="secondary" post="bacterial infection(s) is of critical importance. Antiviral treatments deployed"/>
 <result pre="outcomes. Effective treatment of both the viral and the secondary" exact="bacterial" post="infection(s) is of critical importance. Antiviral treatments deployed initially"/>
 <result pre="of critical importance. Antiviral treatments deployed initially do not treat" exact="secondary" post="bacterial infections (15). The preferred treatment for bacterial infections"/>
 <result pre="critical importance. Antiviral treatments deployed initially do not treat secondary" exact="bacterial infections" post="(15). The preferred treatment for bacterial infections is generally"/>
 <result pre="importance. Antiviral treatments deployed initially do not treat secondary bacterial" exact="infections" post="(15). The preferred treatment for bacterial infections is generally"/>
 <result pre="not treat secondary bacterial infections (15). The preferred treatment for" exact="bacterial infections" post="is generally broad-spectrum antibiotics, but this can result in"/>
 <result pre="treat secondary bacterial infections (15). The preferred treatment for bacterial" exact="infections" post="is generally broad-spectrum antibiotics, but this can result in"/>
 <result pre="a population can be protected from risk of some common" exact="bacterial" post="pathogens that are also capable to cause secondary infections,"/>
 <result pre="some common bacterial pathogens that are also capable to cause" exact="secondary" post="infections, for example pneumonia, if vaccines are available; furthermore,"/>
 <result pre="available; furthermore, the immune system is often capable of fighting" exact="bacterial infections" post="alone, while during a virus-bacterial infection, the complex immune"/>
 <result pre="furthermore, the immune system is often capable of fighting bacterial" exact="infections" post="alone, while during a virus-bacterial infection, the complex immune"/>
 <result pre="the complex immune responses might be inapt to eliminate bacterial-induced" exact="disease" post="complications (19). To reduce severe disease progression or lethal"/>
 <result pre="inapt to eliminate bacterial-induced disease complications (19). To reduce severe" exact="disease" post="progression or lethal outcomes, alternative ways to alleviate complications"/>
 <result pre="or lethal outcomes, alternative ways to alleviate complications due to" exact="secondary" post="bacterial infections and to eliminate bacterial pathogens while preserving"/>
 <result pre="lethal outcomes, alternative ways to alleviate complications due to secondary" exact="bacterial infections" post="and to eliminate bacterial pathogens while preserving host immunity"/>
 <result pre="outcomes, alternative ways to alleviate complications due to secondary bacterial" exact="infections" post="and to eliminate bacterial pathogens while preserving host immunity"/>
 <result pre="alleviate complications due to secondary bacterial infections and to eliminate" exact="bacterial" post="pathogens while preserving host immunity might be necessary. Secondary"/>
 <result pre="eliminate bacterial pathogens while preserving host immunity might be necessary." exact="Secondary" post="infections can also be acquired from the patient's environment"/>
 <result pre="bacterial pathogens while preserving host immunity might be necessary. Secondary" exact="infections" post="can also be acquired from the patient's environment i.e.,"/>
 <result pre="host immunity might be necessary. Secondary infections can also be" exact="acquired" post="from the patient's environment i.e., hospital-acquired or nosocomial infections."/>
 <result pre="also be acquired from the patient's environment i.e., hospital-acquired or" exact="nosocomial infections." post="Nosocomial pathogens are often resistant to a wide range"/>
 <result pre="Carbapenem-resistant Enterobacteriaceae (CRE), Colistin-resistant Klebsiella, Carbapenem-resistant Pseudomonas aeruginosa, and Carbapenem-resistant" exact="Acinetobacter" post="baumannii (20). If a patient with a viral infection"/>
 <result pre="and Carbapenem-resistant Acinetobacter baumannii (20). If a patient with a" exact="viral infection" post="is unfortunate to become infected by MDR bacteria, no"/>
 <result pre="Carbapenem-resistant Acinetobacter baumannii (20). If a patient with a viral" exact="infection" post="is unfortunate to become infected by MDR bacteria, no"/>
 <result pre="more detail below; almost 50% (10 of 21) patients developed" exact="secondary" post="bacterial infections in the lung caused by Klebsiella pneumoniae,"/>
 <result pre="detail below; almost 50% (10 of 21) patients developed secondary" exact="bacterial infections" post="in the lung caused by Klebsiella pneumoniae, Staphylococcus, Acinetobacter"/>
 <result pre="below; almost 50% (10 of 21) patients developed secondary bacterial" exact="infections" post="in the lung caused by Klebsiella pneumoniae, Staphylococcus, Acinetobacter"/>
 <result pre="bacterial infections in the lung caused by Klebsiella pneumoniae, Staphylococcus," exact="Acinetobacter" post="baumannii, and E. coli, ultimately leading to their death,"/>
 <result pre="This evaluation of all the COVID-19 reports available that reference" exact="secondary" post="infections showed that most clinicians prescribed meropenem and linezolid"/>
 <result pre="evaluation of all the COVID-19 reports available that reference secondary" exact="infections" post="showed that most clinicians prescribed meropenem and linezolid to"/>
 <result pre="study, we have assimilated the most recent clinical data on" exact="bacterial" post="secondary infections associated with pneumonias, caused by pulmonary viruses,"/>
 <result pre="we have assimilated the most recent clinical data on bacterial" exact="secondary" post="infections associated with pneumonias, caused by pulmonary viruses, including"/>
 <result pre="have assimilated the most recent clinical data on bacterial secondary" exact="infections" post="associated with pneumonias, caused by pulmonary viruses, including for"/>
 <result pre="data on bacterial secondary infections associated with pneumonias, caused by" exact="pulmonary" post="viruses, including for SARS-CoV-2. We outline treatments used or"/>
 <result pre="SARS-CoV-2. We outline treatments used or prophylactic measures employed for" exact="secondary" post="bacterial infections. This review focuses on secondary bacterial infections"/>
 <result pre="We outline treatments used or prophylactic measures employed for secondary" exact="bacterial infections." post="This review focuses on secondary bacterial infections that occur"/>
 <result pre="measures employed for secondary bacterial infections. This review focuses on" exact="secondary" post="bacterial infections that occur in the respiratory tissue of"/>
 <result pre="employed for secondary bacterial infections. This review focuses on secondary" exact="bacterial infections" post="that occur in the respiratory tissue of patients suffering"/>
 <result pre="for secondary bacterial infections. This review focuses on secondary bacterial" exact="infections" post="that occur in the respiratory tissue of patients suffering"/>
 <result pre="review focuses on secondary bacterial infections that occur in the" exact="respiratory" post="tissue of patients suffering from a viral infection, as"/>
 <result pre="occur in the respiratory tissue of patients suffering from a" exact="viral infection," post="as most lung infections by secondary bacterial pathogens remain"/>
 <result pre="of patients suffering from a viral infection, as most lung" exact="infections" post="by secondary bacterial pathogens remain localized in the respiratory"/>
 <result pre="suffering from a viral infection, as most lung infections by" exact="secondary" post="bacterial pathogens remain localized in the respiratory tract, while"/>
 <result pre="from a viral infection, as most lung infections by secondary" exact="bacterial" post="pathogens remain localized in the respiratory tract, while a"/>
 <result pre="infection, as most lung infections by secondary bacterial pathogens remain" exact="localized" post="in the respiratory tract, while a small percentage leads"/>
 <result pre="lung infections by secondary bacterial pathogens remain localized in the" exact="respiratory" post="tract, while a small percentage leads to infections that"/>
 <result pre="in the respiratory tract, while a small percentage leads to" exact="infections" post="that spread systematically. COVID-19 Related Secondary Bacterial Infections and"/>
 <result pre="small percentage leads to infections that spread systematically. COVID-19 Related" exact="Secondary" post="Bacterial Infections and Treatment SARS-CoV-2 is an enveloped, positive-sense,"/>
 <result pre="percentage leads to infections that spread systematically. COVID-19 Related Secondary" exact="Bacterial Infections" post="and Treatment SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA"/>
 <result pre="leads to infections that spread systematically. COVID-19 Related Secondary Bacterial" exact="Infections" post="and Treatment SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA"/>
 <result pre="Coronaviridae. The virus emerged in 2019 and is responsible for" exact="respiratory" post="illnesses Coronavirus Disease 2019 (COVID-19) that results in respiratory"/>
 <result pre="emerged in 2019 and is responsible for respiratory illnesses Coronavirus" exact="Disease" post="2019 (COVID-19) that results in respiratory tract infections and"/>
 <result pre="for respiratory illnesses Coronavirus Disease 2019 (COVID-19) that results in" exact="respiratory" post="tract infections and causes severe lung damage in most"/>
 <result pre="illnesses Coronavirus Disease 2019 (COVID-19) that results in respiratory tract" exact="infections" post="and causes severe lung damage in most fatal cases."/>
 <result pre="COVID-19 requiring hospitalization and critical care. Early stages of SARS-CoV-2" exact="infection" post="typically include symptoms of mild fever and shortness of"/>
 <result pre="shortness of breath (25). As the virus replicates in the" exact="respiratory" post="tract, the symptoms worsen and once the virus reaches"/>
 <result pre="may result in pneumonia. In almost all severe cases, SARS-CoV-2" exact="infection" post="results in pneumonia and the inflamed fluid-filled alveolar tissue"/>
 <result pre="pneumonia. In almost all severe cases, SARS-CoV-2 infection results in" exact="pneumonia" post="and the inflamed fluid-filled alveolar tissue now is an"/>
 <result pre="inflamed fluid-filled alveolar tissue now is an ideal habitat for" exact="bacterial" post="growth for pathogens including P. aeruginosa and S. aureus."/>
 <result pre="and S. aureus. The causative agent resulting in a severe" exact="disease" post="progression may be bacteria, virus or fungi (26). The"/>
 <result pre="may be bacteria, virus or fungi (26). The presence of" exact="secondary" post="bacterial infections in those infected with SARS-CoV-2 complicates treatment"/>
 <result pre="be bacteria, virus or fungi (26). The presence of secondary" exact="bacterial infections" post="in those infected with SARS-CoV-2 complicates treatment (26, 27)."/>
 <result pre="bacteria, virus or fungi (26). The presence of secondary bacterial" exact="infections" post="in those infected with SARS-CoV-2 complicates treatment (26, 27)."/>
 <result pre="Information, where we have analyzed 15 case studies reporting SARS-CoV-2" exact="infection" post="(Supplemental Data Sheet 1). In particular for data obtained"/>
 <result pre="(azithromycin, moxifloxacin, ceftriaxone, vancomycin, cefepime) to reduce the risk of" exact="nosocomial infections," post="a prophylactic strategy. Should a bacterial infection occur despite"/>
 <result pre="the risk of nosocomial infections, a prophylactic strategy. Should a" exact="bacterial infection" post="occur despite the prophylactic use of antibiotics, caused by"/>
 <result pre="risk of nosocomial infections, a prophylactic strategy. Should a bacterial" exact="infection" post="occur despite the prophylactic use of antibiotics, caused by"/>
 <result pre="in COVID-19 Patients Fifteen clinical reports, for which data for" exact="secondary" post="infections were available, mainly from hospitals in China, were"/>
 <result pre="COVID-19 Patients Fifteen clinical reports, for which data for secondary" exact="infections" post="were available, mainly from hospitals in China, were examined"/>
 <result pre="information of the occurrence, treatment of or prophylactic measures for" exact="bacterial" post="secondary infections during the course of COVID-19 infections (Supplementary"/>
 <result pre="of the occurrence, treatment of or prophylactic measures for bacterial" exact="secondary" post="infections during the course of COVID-19 infections (Supplementary File)."/>
 <result pre="the occurrence, treatment of or prophylactic measures for bacterial secondary" exact="infections" post="during the course of COVID-19 infections (Supplementary File). A"/>
 <result pre="measures for bacterial secondary infections during the course of COVID-19" exact="infections" post="(Supplementary File). A total of 3,133 COVID-19 patient cases"/>
 <result pre="infections during the course of COVID-19 infections (Supplementary File). A" exact="total" post="of 3,133 COVID-19 patient cases were detailed in the"/>
 <result pre="carbapenems, tigecycline, doxycycline, and cefoperazone. In total, 10 studies reported" exact="secondary" post="bacterial infections, with 273 of the 997 patients (27.3%)"/>
 <result pre="tigecycline, doxycycline, and cefoperazone. In total, 10 studies reported secondary" exact="bacterial infections," post="with 273 of the 997 patients (27.3%) being infected."/>
 <result pre="SARS-CoV-2 virus (28, 30, 34, 35, 37). The most common" exact="bacterial infections" post="were caused by the Gram-positive pathogen Staphylococcus aureus or"/>
 <result pre="virus (28, 30, 34, 35, 37). The most common bacterial" exact="infections" post="were caused by the Gram-positive pathogen Staphylococcus aureus or"/>
 <result pre="strains of the Gram-negative bacterium Klebsiella pneumoniae. Five studies reported" exact="infections" post="that were confirmed by tests in a microbiology laboratory,"/>
 <result pre="in 92 of 146 patients (63%), which were administered as" exact="secondary" post="bacterial infections were observed (29, 35, 39). Four studies"/>
 <result pre="92 of 146 patients (63%), which were administered as secondary" exact="bacterial infections" post="were observed (29, 35, 39). Four studies reported complications"/>
 <result pre="of 146 patients (63%), which were administered as secondary bacterial" exact="infections" post="were observed (29, 35, 39). Four studies reported complications"/>
 <result pre="39). Four studies reported complications with fatal outcome due to" exact="bacterial infections" post="that included 41 of 268 patients (15.2%) (26, 27,"/>
 <result pre="Four studies reported complications with fatal outcome due to bacterial" exact="infections" post="that included 41 of 268 patients (15.2%) (26, 27,"/>
 <result pre="and challenges faced in treating SARS-CoV-2 infected patients. Patients with" exact="pneumonia" post="caused by other respiratory viruses or SARS-CoV-2 pneumonia patients"/>
 <result pre="treating SARS-CoV-2 infected patients. Patients with pneumonia caused by other" exact="respiratory" post="viruses or SARS-CoV-2 pneumonia patients were often prophylactically treated"/>
 <result pre="Patients with pneumonia caused by other respiratory viruses or SARS-CoV-2" exact="pneumonia" post="patients were often prophylactically treated with broad-spectrum antibiotics, in"/>
 <result pre="broad-spectrum antibiotics, in an attempt to reduce the risk of" exact="bacterial" post="superinfections. Complications were observed in patients that were not"/>
 <result pre="with antibiotics. Antibiotic-resistant infections, in particular, nosocomial - hospital-acquired -" exact="infections" post="were common for more than one third of ICU"/>
 <result pre="than one third of ICU patients, posing a threat to" exact="disease" post="progression, often resulting in the death of the affected"/>
 <result pre="in the death of the affected individual (26, 40). SARS-related" exact="Secondary" post="Bacterial Infections and Treatment Severe Acute Respiratory Syndrome-related Coronavirus"/>
 <result pre="the death of the affected individual (26, 40). SARS-related Secondary" exact="Bacterial Infections" post="and Treatment Severe Acute Respiratory Syndrome-related Coronavirus (SARS) Co-V,"/>
 <result pre="death of the affected individual (26, 40). SARS-related Secondary Bacterial" exact="Infections" post="and Treatment Severe Acute Respiratory Syndrome-related Coronavirus (SARS) Co-V,"/>
 <result pre="affected individual (26, 40). SARS-related Secondary Bacterial Infections and Treatment" exact="Severe" post="Acute Respiratory Syndrome-related Coronavirus (SARS) Co-V, was first report"/>
 <result pre="individual (26, 40). SARS-related Secondary Bacterial Infections and Treatment Severe" exact="Acute" post="Respiratory Syndrome-related Coronavirus (SARS) Co-V, was first report in"/>
 <result pre="(26, 40). SARS-related Secondary Bacterial Infections and Treatment Severe Acute" exact="Respiratory" post="Syndrome-related Coronavirus (SARS) Co-V, was first report in Guangdong"/>
 <result pre="April 2004 (42). The case studies showed the occurrence of" exact="bacterial" post="co-infections in the large number of patients. These include"/>
 <result pre="bacterial co-infections in the large number of patients. These include" exact="infections" post="by MRSA, Klebsiella spp., P. aeruginosa and Streptococcus (43)."/>
 <result pre="of the SARS patients may be due to the underlining" exact="bacterial infections" post="(43). The use of broad-spectrum antibiotics to cover the"/>
 <result pre="the SARS patients may be due to the underlining bacterial" exact="infections" post="(43). The use of broad-spectrum antibiotics to cover the"/>
 <result pre="infections (43). The use of broad-spectrum antibiotics to cover the" exact="secondary" post="bacterial infections is one of the supportive cares during"/>
 <result pre="(43). The use of broad-spectrum antibiotics to cover the secondary" exact="bacterial infections" post="is one of the supportive cares during SARS outbreak"/>
 <result pre="The use of broad-spectrum antibiotics to cover the secondary bacterial" exact="infections" post="is one of the supportive cares during SARS outbreak"/>
 <result pre="(Supplementary File). The case studies (n = 7) reported the" exact="disease" post="progression of a total of 534 SARS-CoV patients (45–51)"/>
 <result pre="studies (n = 7) reported the disease progression of a" exact="total" post="of 534 SARS-CoV patients (45–51) (Supplementary File). Details about"/>
 <result pre="(n = 206, 74.6%). Of the four studies that reported" exact="secondary" post="bacterial infections, 35 of 306 patients (11.4%) became infected."/>
 <result pre="= 206, 74.6%). Of the four studies that reported secondary" exact="bacterial infections," post="35 of 306 patients (11.4%) became infected. The pathogens"/>
 <result pre="306 patients (11.4%) became infected. The pathogens that caused the" exact="infections" post="included P. aeruginosa, MRSA, S. pneumoniae, K. pneumoniae, Enterococci,"/>
 <result pre="infections included P. aeruginosa, MRSA, S. pneumoniae, K. pneumoniae, Enterococci," exact="Acinetobacter" post="baumannii, Enterobacter, H. influenza, S. maltophilia, and Serratia (45,"/>
 <result pre="studies who provided the respective information) had complications due to" exact="secondary" post="bacterial infections (47, 51). During the 2002 outbreak, most"/>
 <result pre="who provided the respective information) had complications due to secondary" exact="bacterial infections" post="(47, 51). During the 2002 outbreak, most SARS patients"/>
 <result pre="provided the respective information) had complications due to secondary bacterial" exact="infections" post="(47, 51). During the 2002 outbreak, most SARS patients"/>
 <result pre="however the use of antibiotics as a precaution in many" exact="viral" post="infections and their potential overuse may have contributed to"/>
 <result pre="the use of antibiotics as a precaution in many viral" exact="infections" post="and their potential overuse may have contributed to the"/>
 <result pre="overuse may have contributed to the current antibiotic crisis. MERS-related" exact="Secondary" post="Bacterial Infections and Treatment The first cases of the"/>
 <result pre="may have contributed to the current antibiotic crisis. MERS-related Secondary" exact="Bacterial Infections" post="and Treatment The first cases of the Middle East"/>
 <result pre="have contributed to the current antibiotic crisis. MERS-related Secondary Bacterial" exact="Infections" post="and Treatment The first cases of the Middle East"/>
 <result pre="Infections and Treatment The first cases of the Middle East" exact="respiratory" post="syndrome (MERS) CoV epidemic occurred in June 2012 in"/>
 <result pre="and Treatment The first cases of the Middle East respiratory" exact="syndrome" post="(MERS) CoV epidemic occurred in June 2012 in Saudi"/>
 <result pre="= 866), the highest among all coronavirus diseases (52). The" exact="infection" post="often starts as a mild viral respiratory illness but"/>
 <result pre="coronavirus diseases (52). The infection often starts as a mild" exact="viral" post="respiratory illness but can rapidly progress to a fatal"/>
 <result pre="diseases (52). The infection often starts as a mild viral" exact="respiratory" post="illness but can rapidly progress to a fatal viral"/>
 <result pre="viral respiratory illness but can rapidly progress to a fatal" exact="viral pneumonia" post="mostly complicated by ARDS (acute respiratory distress syndrome) and"/>
 <result pre="respiratory illness but can rapidly progress to a fatal viral" exact="pneumonia" post="mostly complicated by ARDS (acute respiratory distress syndrome) and"/>
 <result pre="to a fatal viral pneumonia mostly complicated by ARDS (acute" exact="respiratory" post="distress syndrome) and ARF (acute renal failure) (53). Due"/>
 <result pre="rate of MERS infections, the impact of the occurrence of" exact="bacterial infections" post="remains unclear as death occurs due to hypoxemia and"/>
 <result pre="of MERS infections, the impact of the occurrence of bacterial" exact="infections" post="remains unclear as death occurs due to hypoxemia and"/>
 <result pre="infections remains unclear as death occurs due to hypoxemia and" exact="bilateral" post="interstitial infiltrates in most cases, or ARDS. Nosocomial bacterial"/>
 <result pre="and bilateral interstitial infiltrates in most cases, or ARDS. Nosocomial" exact="bacterial pneumonia" post="is however common among MERS patients with ventilator support."/>
 <result pre="bilateral interstitial infiltrates in most cases, or ARDS. Nosocomial bacterial" exact="pneumonia" post="is however common among MERS patients with ventilator support."/>
 <result pre="with ventilator support. Therefore, antibiotic therapy was commonly deployed with" exact="secondary" post="bacterial infections rarely occurring under this treatment regime (53–55)."/>
 <result pre="ventilator support. Therefore, antibiotic therapy was commonly deployed with secondary" exact="bacterial infections" post="rarely occurring under this treatment regime (53–55). Here, we"/>
 <result pre="support. Therefore, antibiotic therapy was commonly deployed with secondary bacterial" exact="infections" post="rarely occurring under this treatment regime (53–55). Here, we"/>
 <result pre="Here, we review MERS-related case studies, outlining antibiotic therapies and" exact="bacterial infections." post="A total of 138 MERS-CoV infected patients were reported"/>
 <result pre="MERS-related case studies, outlining antibiotic therapies and bacterial infections. A" exact="total" post="of 138 MERS-CoV infected patients were reported (55–59) (Supplementary"/>
 <result pre="other broad-spectrum antibiotics (55, 56, 58, 59). The development of" exact="secondary" post="bacterial infection was reported in two studies, with 32"/>
 <result pre="broad-spectrum antibiotics (55, 56, 58, 59). The development of secondary" exact="bacterial infection" post="was reported in two studies, with 32 of 82"/>
 <result pre="antibiotics (55, 56, 58, 59). The development of secondary bacterial" exact="infection" post="was reported in two studies, with 32 of 82"/>
 <result pre="studies, with 32 of 82 patients experiencing complications due to" exact="bacterial" post="pathogens (55, 57). The most common bacteria were MRSA,"/>
 <result pre="The most common bacteria were MRSA, while others included carbapenem-resistant" exact="Acinetobacter" post="baumannii, VRE and S. pneumoniae. No detailed report was"/>
 <result pre="one study reported (patients n = 15) complications due to" exact="bacterial infections" post="in intensive care units (55). Influenza Viruses and Secondary"/>
 <result pre="study reported (patients n = 15) complications due to bacterial" exact="infections" post="in intensive care units (55). Influenza Viruses and Secondary"/>
 <result pre="bacterial infections in intensive care units (55). Influenza Viruses and" exact="Secondary" post="Bacterial Infections Influenza viruses are known to cause seasonal"/>
 <result pre="infections in intensive care units (55). Influenza Viruses and Secondary" exact="Bacterial Infections" post="Influenza viruses are known to cause seasonal flu every"/>
 <result pre="in intensive care units (55). Influenza Viruses and Secondary Bacterial" exact="Infections" post="Influenza viruses are known to cause seasonal flu every"/>
 <result pre="seasonal flu every year and of the four influenza types," exact="type A" post="and B are known to cause seasonal epidemics (60)."/>
 <result pre="0.25 and 0.5 million people according to the WHO (61)." exact="Secondary" post="bacterial infections are one of the leading causes for"/>
 <result pre="and 0.5 million people according to the WHO (61). Secondary" exact="bacterial infections" post="are one of the leading causes for influenza associated"/>
 <result pre="0.5 million people according to the WHO (61). Secondary bacterial" exact="infections" post="are one of the leading causes for influenza associated"/>
 <result pre="for influenza associated deaths (62). According to the Center for" exact="Disease" post="Control and Prevention (CDC), during the 2009 H1N1 influenza"/>
 <result pre="pandemic between 29 and 55% of mortalities were due to" exact="secondary" post="bacterial infections (63). The lethal synergism between influenza virus"/>
 <result pre="between 29 and 55% of mortalities were due to secondary" exact="bacterial infections" post="(63). The lethal synergism between influenza virus and Pneumococcus"/>
 <result pre="29 and 55% of mortalities were due to secondary bacterial" exact="infections" post="(63). The lethal synergism between influenza virus and Pneumococcus"/>
 <result pre="summarize case studies that are related to influenza viruses and" exact="secondary" post="bacterial infections (Supplementary File). Details on treatment and disease"/>
 <result pre="case studies that are related to influenza viruses and secondary" exact="bacterial infections" post="(Supplementary File). Details on treatment and disease progression of"/>
 <result pre="studies that are related to influenza viruses and secondary bacterial" exact="infections" post="(Supplementary File). Details on treatment and disease progression of"/>
 <result pre="and secondary bacterial infections (Supplementary File). Details on treatment and" exact="disease" post="progression of a total of 910 patients that were"/>
 <result pre="(Supplementary File). Details on treatment and disease progression of a" exact="total" post="of 910 patients that were infected with influenza were"/>
 <result pre="and dicloxacillin. In total, 223 patients of 910 (24.5%) developed" exact="secondary" post="bacterial infections. The infective agents were S. pneumoniae, MRSA,"/>
 <result pre="dicloxacillin. In total, 223 patients of 910 (24.5%) developed secondary" exact="bacterial infections." post="The infective agents were S. pneumoniae, MRSA, P. aeruginosa,"/>
 <result pre="223 patients of 910 (24.5%) developed secondary bacterial infections. The" exact="infective" post="agents were S. pneumoniae, MRSA, P. aeruginosa, S. viridians,"/>
 <result pre="hominis, Enterococci, H. influenza, S. pyogenes, S. mitis, S. agalactiae," exact="Acinetobacter" post="baumannii, E. coli, Chlamydophila pneumoniae, and Moraxella catarrhalis. To"/>
 <result pre="all eight case studies reported the treatment complications due to" exact="secondary" post="bacterial infections. Discussion The lack of detailed clinical data"/>
 <result pre="eight case studies reported the treatment complications due to secondary" exact="bacterial infections." post="Discussion The lack of detailed clinical data regarding secondary"/>
 <result pre="bacterial infections. Discussion The lack of detailed clinical data regarding" exact="secondary" post="bacterial infections following COVID-19, SARS, MERS and influenza is"/>
 <result pre="infections. Discussion The lack of detailed clinical data regarding secondary" exact="bacterial infections" post="following COVID-19, SARS, MERS and influenza is surprising. In"/>
 <result pre="Discussion The lack of detailed clinical data regarding secondary bacterial" exact="infections" post="following COVID-19, SARS, MERS and influenza is surprising. In"/>
 <result pre="addition, precise numbers of clinical cases of COVID-19 or other" exact="respiratory" post="virus infections with antibiotic-resistant secondary bacterial infections are not"/>
 <result pre="numbers of clinical cases of COVID-19 or other respiratory virus" exact="infections" post="with antibiotic-resistant secondary bacterial infections are not available. As"/>
 <result pre="cases of COVID-19 or other respiratory virus infections with antibiotic-resistant" exact="secondary" post="bacterial infections are not available. As globally mortality rates"/>
 <result pre="of COVID-19 or other respiratory virus infections with antibiotic-resistant secondary" exact="bacterial infections" post="are not available. As globally mortality rates from antibiotic-resistant"/>
 <result pre="COVID-19 or other respiratory virus infections with antibiotic-resistant secondary bacterial" exact="infections" post="are not available. As globally mortality rates from antibiotic-resistant"/>
 <result pre="infections are not available. As globally mortality rates from antibiotic-resistant" exact="bacterial infections" post="are increasing, providing such data of secondary infection is"/>
 <result pre="are not available. As globally mortality rates from antibiotic-resistant bacterial" exact="infections" post="are increasing, providing such data of secondary infection is"/>
 <result pre="from antibiotic-resistant bacterial infections are increasing, providing such data of" exact="secondary" post="infection is important, almost critical. Clinical reports are a"/>
 <result pre="antibiotic-resistant bacterial infections are increasing, providing such data of secondary" exact="infection" post="is important, almost critical. Clinical reports are a valuable"/>
 <result pre="pathogenic bacterium. Such data are essential for the study of" exact="secondary" post="infections in human patients; the scientific community and ultimately"/>
 <result pre="bacterium. Such data are essential for the study of secondary" exact="infections" post="in human patients; the scientific community and ultimately the"/>
 <result pre="and ultimately the patient will benefit when clinicians and non-clinical" exact="disease" post="experts work close together. The information from such collaborative"/>
 <result pre="is evident. Reviewing the available information, it becomes clear that" exact="secondary" post="bacterial infections play a critical role in the morbidity"/>
 <result pre="evident. Reviewing the available information, it becomes clear that secondary" exact="bacterial infections" post="play a critical role in the morbidity and mortality"/>
 <result pre="Reviewing the available information, it becomes clear that secondary bacterial" exact="infections" post="play a critical role in the morbidity and mortality"/>
 <result pre="morbidity and mortality rates of patients initially falling ill with" exact="pulmonary" post="viral diseases. Similar to epidemics caused by influenza viruses,"/>
 <result pre="and mortality rates of patients initially falling ill with pulmonary" exact="viral" post="diseases. Similar to epidemics caused by influenza viruses, during"/>
 <result pre="caused by influenza viruses, during the current SARS-CoV-2 pandemic, antibiotic-resistant" exact="bacterial infections" post="are a significant threat to the well-being of hospitalized"/>
 <result pre="by influenza viruses, during the current SARS-CoV-2 pandemic, antibiotic-resistant bacterial" exact="infections" post="are a significant threat to the well-being of hospitalized"/>
 <result pre="significant threat to the well-being of hospitalized COVID-19 patients. Nosocomial" exact="infections" post="including ventilator-associated infections are often unavoidable and especially so"/>
 <result pre="the well-being of hospitalized COVID-19 patients. Nosocomial infections including ventilator-associated" exact="infections" post="are often unavoidable and especially so during a pandemic."/>
 <result pre="this date unavailable preventive measures are in place at hospitals," exact="secondary" post="infections will remain unavoidable due to the nature of"/>
 <result pre="date unavailable preventive measures are in place at hospitals, secondary" exact="infections" post="will remain unavoidable due to the nature of nosocomial"/>
 <result pre="populations until a vaccine is deployed, globally. To prepare for" exact="recurrent" post="waves of COVID-19 disease and the inevitable next new"/>
 <result pre="is deployed, globally. To prepare for recurrent waves of COVID-19" exact="disease" post="and the inevitable next new pandemic, new antibiotics or"/>
 <result pre="next new pandemic, new antibiotics or alternative treatments targeted against" exact="secondary" post="bacterial infections are needed. Alternative therapies such as Antimicrobial"/>
 <result pre="new pandemic, new antibiotics or alternative treatments targeted against secondary" exact="bacterial infections" post="are needed. Alternative therapies such as Antimicrobial Peptides or"/>
 <result pre="pandemic, new antibiotics or alternative treatments targeted against secondary bacterial" exact="infections" post="are needed. Alternative therapies such as Antimicrobial Peptides or"/>
 <result pre="show promise. Most antimicrobial peptides perturb the structure of the" exact="bacterial" post="cell envelope while not affecting the eukaryotic cell membrane;"/>
 <result pre="cell membrane; eventually creating a leaky lipid bilayer and the" exact="collapse" post="of the proton-motif-force, ultimately resulting in bacterial cell death"/>
 <result pre="bilayer and the collapse of the proton-motif-force, ultimately resulting in" exact="bacterial" post="cell death (73–76). Phage therapy makes use of bacterial"/>
 <result pre="in bacterial cell death (73–76). Phage therapy makes use of" exact="bacterial" post="viruses (or bacteriophages) that specifically infect bacterial pathogens for"/>
 <result pre="makes use of bacterial viruses (or bacteriophages) that specifically infect" exact="bacterial" post="pathogens for viral replication, which leads to the lysis"/>
 <result pre="bacterial viruses (or bacteriophages) that specifically infect bacterial pathogens for" exact="viral" post="replication, which leads to the lysis of the host"/>
 <result pre="that do not kill or arrest the growth of a" exact="bacterial" post="pathogen, but rather target pathogen-intrinsic components important for the"/>
 <result pre="bacterial pathogen, but rather target pathogen-intrinsic components important for the" exact="infection" post="process. These include bacterial components such as exo- and"/>
 <result pre="target pathogen-intrinsic components important for the infection process. These include" exact="bacterial" post="components such as exo- and endotoxins, i.e., actively secreted"/>
 <result pre="demonstrated to prevent or reduce the severity of symptoms of" exact="acute" post="infections (84, 85). Pulmonary coronaviruses will likely be a"/>
 <result pre="to prevent or reduce the severity of symptoms of acute" exact="infections" post="(84, 85). Pulmonary coronaviruses will likely be a clinical"/>
 <result pre="reduce the severity of symptoms of acute infections (84, 85)." exact="Pulmonary" post="coronaviruses will likely be a clinical challenge for many"/>
 <result pre="likely be a clinical challenge for many years to come." exact="Viral" post="pandemics from coronaviruses and emerging pathogens are inevitable in"/>
 <result pre="the next pandemic, exploring and establishing new avenues to treat" exact="bacterial" post="pathogens commonly observed in secondary infections to avert a"/>
 <result pre="establishing new avenues to treat bacterial pathogens commonly observed in" exact="secondary" post="infections to avert a healthcare crisis due to antibiotic-resistance."/>
 <result pre="new avenues to treat bacterial pathogens commonly observed in secondary" exact="infections" post="to avert a healthcare crisis due to antibiotic-resistance. Author"/>
 <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
 <result pre="https://www.frontiersin.org/articles/10.3389/fmed.2020.00420/full#supplementary-material Supplementary Figure 1 Overview of case reports of SARS-CoV-2" exact="infection" post="data reviewed in this study, including rate of secondary"/>
 <result pre="SARS-CoV-2 infection data reviewed in this study, including rate of" exact="secondary" post="bacterial infections, antibiotic use and pathogenic bacteria identified. LINK"/>
 <result pre="infection data reviewed in this study, including rate of secondary" exact="bacterial infections," post="antibiotic use and pathogenic bacteria identified. LINK Click here"/>
 <result pre="file. Supplementary File Tables summarizing case reports of patients with" exact="pulmonary" post="virus infections and clinical interventions to prevent or cure"/>
 <result pre="File Tables summarizing case reports of patients with pulmonary virus" exact="infections" post="and clinical interventions to prevent or cure secondary bacterial"/>
 <result pre="pulmonary virus infections and clinical interventions to prevent or cure" exact="secondary" post="bacterial infections. LINK Click here for additional data file."/>
 <result pre="virus infections and clinical interventions to prevent or cure secondary" exact="bacterial infections." post="LINK Click here for additional data file. Supplemental Data"/>
 <result pre="file. Supplemental Data Sheet 1 Case reports of patients with" exact="secondary" post="bacterial infections. LINK Click here for additional data file."/>
 <result pre="Supplemental Data Sheet 1 Case reports of patients with secondary" exact="bacterial infections." post="LINK Click here for additional data file. References References"/>
 <result pre="Click here for additional data file. References References 1.BradleyBTBryanA. Emerging" exact="respiratory" post="Infections: The infectious disease pathology of SARS, MERS, pandemic"/>
 <result pre="additional data file. References References 1.BradleyBTBryanA. Emerging respiratory Infections: The" exact="infectious disease" post="pathology of SARS, MERS, pandemic influenza, and Legionella. Semin"/>
 <result pre="data file. References References 1.BradleyBTBryanA. Emerging respiratory Infections: The infectious" exact="disease" post="pathology of SARS, MERS, pandemic influenza, and Legionella. Semin"/>
 <result pre="influenza, and Legionella. Semin Diagn Pathol. (2019) 36:152–9. 10.1053/j.semdp.2019.04.00631054790 2.MorrisDEClearyDWClarkeSC." exact="Secondary" post="bacterial infections associated with influenza pandemics. Front Microbiol. (2017)"/>
 <result pre="and Legionella. Semin Diagn Pathol. (2019) 36:152–9. 10.1053/j.semdp.2019.04.00631054790 2.MorrisDEClearyDWClarkeSC. Secondary" exact="bacterial infections" post="associated with influenza pandemics. Front Microbiol. (2017) 8:1041. 10.3389/fmicb.2017.0104128690590"/>
 <result pre="Legionella. Semin Diagn Pathol. (2019) 36:152–9. 10.1053/j.semdp.2019.04.00631054790 2.MorrisDEClearyDWClarkeSC. Secondary bacterial" exact="infections" post="associated with influenza pandemics. Front Microbiol. (2017) 8:1041. 10.3389/fmicb.2017.0104128690590"/>
 <result pre="influenza pandemics. Front Microbiol. (2017) 8:1041. 10.3389/fmicb.2017.0104128690590 3.WangHAnthonyDSelemidisSVlahosRBozinovskiS. Resolving viral-induced" exact="secondary" post="bacterial infection in COPD: a concise review. Front Immunol."/>
 <result pre="pandemics. Front Microbiol. (2017) 8:1041. 10.3389/fmicb.2017.0104128690590 3.WangHAnthonyDSelemidisSVlahosRBozinovskiS. Resolving viral-induced secondary" exact="bacterial infection" post="in COPD: a concise review. Front Immunol. (2018) 9:2345."/>
 <result pre="Front Microbiol. (2017) 8:1041. 10.3389/fmicb.2017.0104128690590 3.WangHAnthonyDSelemidisSVlahosRBozinovskiS. Resolving viral-induced secondary bacterial" exact="infection" post="in COPD: a concise review. Front Immunol. (2018) 9:2345."/>
 <result pre="concise review. Front Immunol. (2018) 9:2345. 10.3389/fimmu.2018.0234530459754 4.MalliaPFootittJSoteroRJepsonAContoliMTrujillo-TorralboMBet al.. Rhinovirus" exact="infection" post="induces degradation of antimicrobial peptides and secondary bacterial infection"/>
 <result pre="4.MalliaPFootittJSoteroRJepsonAContoliMTrujillo-TorralboMBet al.. Rhinovirus infection induces degradation of antimicrobial peptides and" exact="secondary" post="bacterial infection in chronic obstructive pulmonary disease. Am J"/>
 <result pre="al.. Rhinovirus infection induces degradation of antimicrobial peptides and secondary" exact="bacterial infection" post="in chronic obstructive pulmonary disease. Am J Respir Crit"/>
 <result pre="Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial" exact="infection" post="in chronic obstructive pulmonary disease. Am J Respir Crit"/>
 <result pre="induces degradation of antimicrobial peptides and secondary bacterial infection in" exact="chronic" post="obstructive pulmonary disease. Am J Respir Crit Care Med."/>
 <result pre="of antimicrobial peptides and secondary bacterial infection in chronic obstructive" exact="pulmonary" post="disease. Am J Respir Crit Care Med. (2012) 186:1117–24."/>
 <result pre="influenza: a grand rounds review. JAMA. (2013) 309:275–82. 10.1001/jama.2012.19413923321766 6.KashJCTaubenbergerJKInfectious" exact="disease" post="theme issue the role of viral, host, and secondary"/>
 <result pre="6.KashJCTaubenbergerJKInfectious disease theme issue the role of viral, host, and" exact="secondary" post="bacterial factors in influenza pathogenesis. Am J Pathol. (2015)"/>
 <result pre="disease theme issue the role of viral, host, and secondary" exact="bacterial" post="factors in influenza pathogenesis. Am J Pathol. (2015) 185:1528–36."/>
 <result pre="J Pathol. (2015) 185:1528–36. 10.1016/j.ajpath.2014.08.03025747532 7.MacIntyreCRChughtaiAABarnesMRiddaISealeHTomsRet al.. The role of" exact="pneumonia" post="and secondary bacterial infection in fatal and serious outcomes"/>
 <result pre="(2015) 185:1528–36. 10.1016/j.ajpath.2014.08.03025747532 7.MacIntyreCRChughtaiAABarnesMRiddaISealeHTomsRet al.. The role of pneumonia and" exact="secondary" post="bacterial infection in fatal and serious outcomes of pandemic"/>
 <result pre="185:1528–36. 10.1016/j.ajpath.2014.08.03025747532 7.MacIntyreCRChughtaiAABarnesMRiddaISealeHTomsRet al.. The role of pneumonia and secondary" exact="bacterial infection" post="in fatal and serious outcomes of pandemic influenza a"/>
 <result pre="10.1016/j.ajpath.2014.08.03025747532 7.MacIntyreCRChughtaiAABarnesMRiddaISealeHTomsRet al.. The role of pneumonia and secondary bacterial" exact="infection" post="in fatal and serious outcomes of pandemic influenza a"/>
 <result pre="(H1N1) pdm09. BMC Infect Dis. (2018) 18:637. 10.1186/s12879-018-3548-030526505 8.KimYGParkJHReimerTBakerDPKawaiTKumarHet al.." exact="Viral" post="infection augments Nod1/2 signaling to potentiate lethality associated with"/>
 <result pre="pdm09. BMC Infect Dis. (2018) 18:637. 10.1186/s12879-018-3548-030526505 8.KimYGParkJHReimerTBakerDPKawaiTKumarHet al.. Viral" exact="infection" post="augments Nod1/2 signaling to potentiate lethality associated with secondary"/>
 <result pre="Viral infection augments Nod1/2 signaling to potentiate lethality associated with" exact="secondary" post="bacterial infections. Cell Host Microbe. (2011) 9:496–507. 10.1016/j.chom.2011.05.00621669398 9.JamiesonAMYuSAnnicelliCHMedzhitovR."/>
 <result pre="infection augments Nod1/2 signaling to potentiate lethality associated with secondary" exact="bacterial infections." post="Cell Host Microbe. (2011) 9:496–507. 10.1016/j.chom.2011.05.00621669398 9.JamiesonAMYuSAnnicelliCHMedzhitovR. Article influenza"/>
 <result pre="Article influenza virus-induced glucocorticoids compromise innate host defense against a" exact="secondary" post="bacterial infection. Cell Host Microbe. (2010) 7:103–14. 10.1016/j.chom.2010.01.01020159617 10.HendausMAJomhaFAAlhammadiAH."/>
 <result pre="influenza virus-induced glucocorticoids compromise innate host defense against a secondary" exact="bacterial infection." post="Cell Host Microbe. (2010) 7:103–14. 10.1016/j.chom.2010.01.01020159617 10.HendausMAJomhaFAAlhammadiAH. Virus-induced secondary"/>
 <result pre="bacterial infection. Cell Host Microbe. (2010) 7:103–14. 10.1016/j.chom.2010.01.01020159617 10.HendausMAJomhaFAAlhammadiAH. Virus-induced" exact="secondary" post="bacterial infection: a concise review. Ther Clin Risk Manag."/>
 <result pre="infection. Cell Host Microbe. (2010) 7:103–14. 10.1016/j.chom.2010.01.01020159617 10.HendausMAJomhaFAAlhammadiAH. Virus-induced secondary" exact="bacterial" post="infection: a concise review. Ther Clin Risk Manag. (2015)"/>
 <result pre="review. Ther Clin Risk Manag. (2015) 11:1265–71. 10.2147/TCRM.S8778926345407 11.NyangachaRMOdongoDOyiekeFOchwotoMKorirRNgetichRKet al.." exact="Secondary" post="bacterial infections and antibiotic resistance among tungiasis patients in"/>
 <result pre="Ther Clin Risk Manag. (2015) 11:1265–71. 10.2147/TCRM.S8778926345407 11.NyangachaRMOdongoDOyiekeFOchwotoMKorirRNgetichRKet al.. Secondary" exact="bacterial infections" post="and antibiotic resistance among tungiasis patients in Western, Kenya."/>
 <result pre="Clin Risk Manag. (2015) 11:1265–71. 10.2147/TCRM.S8778926345407 11.NyangachaRMOdongoDOyiekeFOchwotoMKorirRNgetichRKet al.. Secondary bacterial" exact="infections" post="and antibiotic resistance among tungiasis patients in Western, Kenya."/>
 <result pre="10.2147/TCRM.S8778926345407 11.NyangachaRMOdongoDOyiekeFOchwotoMKorirRNgetichRKet al.. Secondary bacterial infections and antibiotic resistance among" exact="tungiasis" post="patients in Western, Kenya. PLoS Neglect Trop D. (2017)"/>
 <result pre="Kenya. PLoS Neglect Trop D. (2017) 11:e0005901. 10.1371/journal.pntd.000590128886013 12.PittetLAHall-StoodleyLRutkowskiMRHarmsenAG. Influenza" exact="virus infection" post="decreases tracheal mucociliary velocity and clearance of Streptococcus pneumoniae."/>
 <result pre="PLoS Neglect Trop D. (2017) 11:e0005901. 10.1371/journal.pntd.000590128886013 12.PittetLAHall-StoodleyLRutkowskiMRHarmsenAG. Influenza virus" exact="infection" post="decreases tracheal mucociliary velocity and clearance of Streptococcus pneumoniae."/>
 <result pre="Resp Cell Mol. (2010) 42:450–60. 10.1165/rcmb.2007-0417OC19520922 13.MorrisDP. Bacterial biofilm in" exact="upper" post="respiratory tract infections. Curr Infect Dis Rep. (2007) 9:186–92."/>
 <result pre="Cell Mol. (2010) 42:450–60. 10.1165/rcmb.2007-0417OC19520922 13.MorrisDP. Bacterial biofilm in upper" exact="respiratory" post="tract infections. Curr Infect Dis Rep. (2007) 9:186–92. 10.1007/s11908-007-0030-317430699"/>
 <result pre="14.HandelALonginiIMAntiaR. Intervention strategies for an influenza pandemic taking into account" exact="secondary" post="bacterial infections. Epidem. (2009) 1:185–95. 10.1016/j.epidem.2009.09.00120161493 15.McCullersJA. Preventing and"/>
 <result pre="Intervention strategies for an influenza pandemic taking into account secondary" exact="bacterial infections." post="Epidem. (2009) 1:185–95. 10.1016/j.epidem.2009.09.00120161493 15.McCullersJA. Preventing and treating secondary"/>
 <result pre="bacterial infections. Epidem. (2009) 1:185–95. 10.1016/j.epidem.2009.09.00120161493 15.McCullersJA. Preventing and treating" exact="secondary" post="bacterial infections with antiviral agents. Antivir Ther. (2011) 16:123–35."/>
 <result pre="infections. Epidem. (2009) 1:185–95. 10.1016/j.epidem.2009.09.00120161493 15.McCullersJA. Preventing and treating secondary" exact="bacterial infections" post="with antiviral agents. Antivir Ther. (2011) 16:123–35. 10.3851/IMP173021447860 16.BrookI."/>
 <result pre="Epidem. (2009) 1:185–95. 10.1016/j.epidem.2009.09.00120161493 15.McCullersJA. Preventing and treating secondary bacterial" exact="infections" post="with antiviral agents. Antivir Ther. (2011) 16:123–35. 10.3851/IMP173021447860 16.BrookI."/>
 <result pre="infections with antiviral agents. Antivir Ther. (2011) 16:123–35. 10.3851/IMP173021447860 16.BrookI." exact="Secondary" post="bacterial infections complicating skin lesions. J Med Microbiol. (2002)"/>
 <result pre="with antiviral agents. Antivir Ther. (2011) 16:123–35. 10.3851/IMP173021447860 16.BrookI. Secondary" exact="bacterial infections" post="complicating skin lesions. J Med Microbiol. (2002) 51:808–12. 10.1099/0022-1317-51-10-80812435058"/>
 <result pre="antiviral agents. Antivir Ther. (2011) 16:123–35. 10.3851/IMP173021447860 16.BrookI. Secondary bacterial" exact="infections" post="complicating skin lesions. J Med Microbiol. (2002) 51:808–12. 10.1099/0022-1317-51-10-80812435058"/>
 <result pre="lesions. J Med Microbiol. (2002) 51:808–12. 10.1099/0022-1317-51-10-80812435058 17.BrookI. Microbiology of" exact="secondary" post="bacterial infection in scabies lesions. J Clin Microbiol. (1995)"/>
 <result pre="J Med Microbiol. (2002) 51:808–12. 10.1099/0022-1317-51-10-80812435058 17.BrookI. Microbiology of secondary" exact="bacterial infection" post="in scabies lesions. J Clin Microbiol. (1995) 33:2139–40. 10.1128/JCM.33.8.2139-2140.19957559963"/>
 <result pre="Med Microbiol. (2002) 51:808–12. 10.1099/0022-1317-51-10-80812435058 17.BrookI. Microbiology of secondary bacterial" exact="infection" post="in scabies lesions. J Clin Microbiol. (1995) 33:2139–40. 10.1128/JCM.33.8.2139-2140.19957559963"/>
 <result pre="(2002) 51:808–12. 10.1099/0022-1317-51-10-80812435058 17.BrookI. Microbiology of secondary bacterial infection in" exact="scabies" post="lesions. J Clin Microbiol. (1995) 33:2139–40. 10.1128/JCM.33.8.2139-2140.19957559963 18.MaharPDWasiakJClelandHPaulEGinDWattersDAet al.."/>
 <result pre="scabies lesions. J Clin Microbiol. (1995) 33:2139–40. 10.1128/JCM.33.8.2139-2140.19957559963 18.MaharPDWasiakJClelandHPaulEGinDWattersDAet al.." exact="Secondary" post="bacterial infection and empirical antibiotic use in toxic epidermal"/>
 <result pre="lesions. J Clin Microbiol. (1995) 33:2139–40. 10.1128/JCM.33.8.2139-2140.19957559963 18.MaharPDWasiakJClelandHPaulEGinDWattersDAet al.. Secondary" exact="bacterial infection" post="and empirical antibiotic use in toxic epidermal necrolysis patients."/>
 <result pre="J Clin Microbiol. (1995) 33:2139–40. 10.1128/JCM.33.8.2139-2140.19957559963 18.MaharPDWasiakJClelandHPaulEGinDWattersDAet al.. Secondary bacterial" exact="infection" post="and empirical antibiotic use in toxic epidermal necrolysis patients."/>
 <result pre="18.MaharPDWasiakJClelandHPaulEGinDWattersDAet al.. Secondary bacterial infection and empirical antibiotic use in" exact="toxic epidermal necrolysis" post="patients. J Burn Care Res. (2014) 35:518–24. 10.1097/BCR.000000000000006224988228 19.SmithAMMcCullersJASecondary"/>
 <result pre="necrolysis patients. J Burn Care Res. (2014) 35:518–24. 10.1097/BCR.000000000000006224988228 19.SmithAMMcCullersJASecondary" exact="bacterial infections" post="in influenza virus infection pathogenesis in influenza pathogenesis and"/>
 <result pre="patients. J Burn Care Res. (2014) 35:518–24. 10.1097/BCR.000000000000006224988228 19.SmithAMMcCullersJASecondary bacterial" exact="infections" post="in influenza virus infection pathogenesis in influenza pathogenesis and"/>
 <result pre="Care Res. (2014) 35:518–24. 10.1097/BCR.000000000000006224988228 19.SmithAMMcCullersJASecondary bacterial infections in influenza" exact="virus infection" post="pathogenesis in influenza pathogenesis and control. Curr Top Microbiol"/>
 <result pre="Res. (2014) 35:518–24. 10.1097/BCR.000000000000006224988228 19.SmithAMMcCullersJASecondary bacterial infections in influenza virus" exact="infection" post="pathogenesis in influenza pathogenesis and control. Curr Top Microbiol"/>
 <result pre="antibiotics. In: Arora G, Sajid A, Kalia VC, editors. Drug" exact="Resistance" post="in Bacteria, Fungi, Malaria, and Cancer. Cham: Springer (2017)."/>
 <result pre="a multidisciplinary future of phage therapy to combat multi-drug resistant" exact="bacterial infections." post="Infect Microb Dis. (2020) 2:1–2. 10.1097/IM9.0000000000000018 23.DuRHLiangLRYangCQWangWCaoTZLiMet al.. Predictors"/>
 <result pre="10.1097/IM9.0000000000000018 23.DuRHLiangLRYangCQWangWCaoTZLiMet al.. Predictors of mortality for patients with COVID-19" exact="pneumonia" post="caused by SARS-CoV-2: a prospective cohort study. Eur Respir"/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive study. Lancet. (2020) 395:507–13."/>
 <result pre="Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational study. Lancet"/>
 <result pre="27.ZhouFYuTDuRFanGLiuYLiuZet al.. Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
 <result pre="Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected" exact="pneumonia" post="in Wuhan, China. JAMA. (2020) 323:1061–9. 10.1001/jama.2020.158532031570 29.HolshueMLDeBoltCLindquistSLofyKHWiesmanJBruceHet al.First"/>
 <result pre="J Med. (2020) 382:929–36. 10.1056/NEJMoa200119132004427 30.GuanWJNiZYHuYLiangWHOuCQHeJXet al.Clinical characteristics of coronavirus" exact="disease" post="2019 in China. N Engl J Med. (2020) 382:1708–20."/>
 <result pre="Med. (2020) 3:1–3. 10.1007/s00134-020-06028-z 32.WuCChenXCaiYZhouXXuSHuangHet al.. Risk factors associated with" exact="acute" post="respiratory distress syndrome and death in patients with coronavirus"/>
 <result pre="(2020) 3:1–3. 10.1007/s00134-020-06028-z 32.WuCChenXCaiYZhouXXuSHuangHet al.. Risk factors associated with acute" exact="respiratory" post="distress syndrome and death in patients with coronavirus disease"/>
 <result pre="10.1007/s00134-020-06028-z 32.WuCChenXCaiYZhouXXuSHuangHet al.. Risk factors associated with acute respiratory distress" exact="syndrome" post="and death in patients with coronavirus disease 2019 pneumonia"/>
 <result pre="acute respiratory distress syndrome and death in patients with coronavirus" exact="disease" post="2019 pneumonia in Wuhan, China. JAMA Intern Med. (2020)"/>
 <result pre="distress syndrome and death in patients with coronavirus disease 2019" exact="pneumonia" post="in Wuhan, China. JAMA Intern Med. (2020) 180:1–11. 10.1001/jamainternmed.2020.099432167524"/>
 <result pre="patients assessed for COVID-19 infection; experience from a UK regional" exact="infectious disease" post="unit. Influenza Other Respir Viruses. (2020) 14:374–9. 10.1111/irv.1273932223012 37.ChenTWuDChenHYanWYangDChenGet"/>
 <result pre="assessed for COVID-19 infection; experience from a UK regional infectious" exact="disease" post="unit. Influenza Other Respir Viruses. (2020) 14:374–9. 10.1111/irv.1273932223012 37.ChenTWuDChenHYanWYangDChenGet"/>
 <result pre="37.ChenTWuDChenHYanWYangDChenGet al.. Clinical characteristics of 113 deceased patients with coronavirus" exact="disease" post="2019: retrospective study. BMJ. (2020) 368:m1295. 10.1136/bmj.m129532234718 38.WangZYangBLiQWenLZhangRClinical features"/>
 <result pre="(2020) 368:m1295. 10.1136/bmj.m129532234718 38.WangZYangBLiQWenLZhangRClinical features of 69 cases with coronavirus" exact="disease" post="2019 in Wuhan, China. Clin Infect Dis. (2020) ciaa27210.1093/cid/ciaa272."/>
 <result pre="China. Int J Infect Dis. (2020) 95:421–8. 10.1016/j.ijid.2020.03.07032289565 40.RichardsMJEdwardsJRCulverDHGaynesRP. Nosocomial" exact="infections" post="in medical intensive care units in the United States."/>
 <result pre="http://www.who.int/csr/sars/country/table2004_04_21/en/ 42.Available, online at: http://www.who.int/csr/don/archive/disease/severe_acute_respiratory_syndrome/en/index.html 43.GuJKortewegCPathology and pathogenesis of severe" exact="acute" post="respiratory syndrome. Am J Pathol. (2007) 170:1136–47. 10.2353/ajpath.2007.06108817392154 44.ChengVCChanJFToKKYuenKY."/>
 <result pre="42.Available, online at: http://www.who.int/csr/don/archive/disease/severe_acute_respiratory_syndrome/en/index.html 43.GuJKortewegCPathology and pathogenesis of severe acute" exact="respiratory" post="syndrome. Am J Pathol. (2007) 170:1136–47. 10.2353/ajpath.2007.06108817392154 44.ChengVCChanJFToKKYuenKY. Clinical"/>
 <result pre="Am J Pathol. (2007) 170:1136–47. 10.2353/ajpath.2007.06108817392154 44.ChengVCChanJFToKKYuenKY. Clinical management and" exact="infection" post="control of SARS: lessons learned. Antiviral Res. (2013) 100:407–19."/>
 <result pre="100:407–19. 10.1016/j.antiviral.2013.08.01623994190 45.ChongPYChuiPLingAEFranksTJTaiDYLeoYSet al.. Analysis of deaths during the severe" exact="acute" post="respiratory syndrome (SARS) epidemic in Singapore: challenges in determining"/>
 <result pre="10.1016/j.antiviral.2013.08.01623994190 45.ChongPYChuiPLingAEFranksTJTaiDYLeoYSet al.. Analysis of deaths during the severe acute" exact="respiratory" post="syndrome (SARS) epidemic in Singapore: challenges in determining a"/>
 <result pre="45.ChongPYChuiPLingAEFranksTJTaiDYLeoYSet al.. Analysis of deaths during the severe acute respiratory" exact="syndrome" post="(SARS) epidemic in Singapore: challenges in determining a SARS"/>
 <result pre="46.SoLKLauACYamLYCheungTMPoonEYungRWet al.. Development of a standard treatment protocol for severe" exact="acute" post="respiratory syndrome. Lancet. (2003) 361:1615–7. 10.1016/S0140-6736(03)13265-512747883 47.LeeNHuiDWuAChanPCameronPJoyntGMet al.. A"/>
 <result pre="al.. Development of a standard treatment protocol for severe acute" exact="respiratory" post="syndrome. Lancet. (2003) 361:1615–7. 10.1016/S0140-6736(03)13265-512747883 47.LeeNHuiDWuAChanPCameronPJoyntGMet al.. A major"/>
 <result pre="(2003) 361:1615–7. 10.1016/S0140-6736(03)13265-512747883 47.LeeNHuiDWuAChanPCameronPJoyntGMet al.. A major outbreak of severe" exact="acute" post="respiratory syndrome in Hong Kong. N Engl J Med."/>
 <result pre="361:1615–7. 10.1016/S0140-6736(03)13265-512747883 47.LeeNHuiDWuAChanPCameronPJoyntGMet al.. A major outbreak of severe acute" exact="respiratory" post="syndrome in Hong Kong. N Engl J Med. (2003)"/>
 <result pre="10.1016/S0140-6736(03)13265-512747883 47.LeeNHuiDWuAChanPCameronPJoyntGMet al.. A major outbreak of severe acute respiratory" exact="syndrome" post="in Hong Kong. N Engl J Med. (2003) 348:1986–94."/>
 <result pre="348:1986–94. 10.1056/NEJMoa03068512682352 48.TsangKWHoPLOoiGCYeeWKWangTChan-YeungMet al.. A cluster of cases of severe" exact="acute" post="respiratory syndrome in Hong Kong. N Engl J Med."/>
 <result pre="10.1056/NEJMoa03068512682352 48.TsangKWHoPLOoiGCYeeWKWangTChan-YeungMet al.. A cluster of cases of severe acute" exact="respiratory" post="syndrome in Hong Kong. N Engl J Med. (2003)"/>
 <result pre="48.TsangKWHoPLOoiGCYeeWKWangTChan-YeungMet al.. A cluster of cases of severe acute respiratory" exact="syndrome" post="in Hong Kong. N Engl J Med. (2003) 348:1977–85."/>
 <result pre="J Med. (2003) 348:1977–85. 10.1056/NEJMoa03066612671062 49.PeirisJSChuCMChengVCChanKSHungIFPoonLLet al.. Clinical progression and" exact="viral" post="load in a community outbreak of coronavirus-associated SARS pneumonia:"/>
 <result pre="Description and clinical treatment of an early outbreak of severe" exact="acute" post="respiratory syndrome (SARS) in Guangzhou, PR China. J Med"/>
 <result pre="and clinical treatment of an early outbreak of severe acute" exact="respiratory" post="syndrome (SARS) in Guangzhou, PR China. J Med Microbiol."/>
 <result pre="clinical treatment of an early outbreak of severe acute respiratory" exact="syndrome" post="(SARS) in Guangzhou, PR China. J Med Microbiol. (2003)"/>
 <result pre="Dis. (2004) 10:818–24. 10.3201/eid1005.03064015200814 52.Available, online at: https://www.who.int/csr/don/24-february-2020-mers-saudi-arabia/en/ 53.CunhaCBOpalSMMiddle east" exact="respiratory" post="syndrome (MERS) A new zoonotic viral pneumonia. Virulence. (2014)"/>
 <result pre="(2004) 10:818–24. 10.3201/eid1005.03064015200814 52.Available, online at: https://www.who.int/csr/don/24-february-2020-mers-saudi-arabia/en/ 53.CunhaCBOpalSMMiddle east respiratory" exact="syndrome" post="(MERS) A new zoonotic viral pneumonia. Virulence. (2014) 5:650–4."/>
 <result pre="at: https://www.who.int/csr/don/24-february-2020-mers-saudi-arabia/en/ 53.CunhaCBOpalSMMiddle east respiratory syndrome (MERS) A new zoonotic" exact="viral pneumonia." post="Virulence. (2014) 5:650–4. 10.4161/viru.3207725089913 54.MemishZACottenMWatsonSJKellamPZumlaAAlhakeemRFet al.. Community case clusters"/>
 <result pre="5:650–4. 10.4161/viru.3207725089913 54.MemishZACottenMWatsonSJKellamPZumlaAAlhakeemRFet al.. Community case clusters of middle east" exact="respiratory" post="syndrome coronavirus in Hafr Al-Batin, Kingdom of Saudi Arabia:"/>
 <result pre="10.4161/viru.3207725089913 54.MemishZACottenMWatsonSJKellamPZumlaAAlhakeemRFet al.. Community case clusters of middle east respiratory" exact="syndrome" post="coronavirus in Hafr Al-Batin, Kingdom of Saudi Arabia: a"/>
 <result pre="course and outcomes of critically ill patients with middle east" exact="respiratory" post="syndrome coronavirus infection. Ann Intern Med. (2014) 160:389–97. 10.7326/M13-248624474051"/>
 <result pre="and outcomes of critically ill patients with middle east respiratory" exact="syndrome" post="coronavirus infection. Ann Intern Med. (2014) 160:389–97. 10.7326/M13-248624474051 56.Al-TawfiqJAMomattinHDibJMemishZA."/>
 <result pre="and interferon therapy in patients infected with the middle east" exact="respiratory" post="syndrome coronavirus: an observational study. Int J Infect Dis."/>
 <result pre="interferon therapy in patients infected with the middle east respiratory" exact="syndrome" post="coronavirus: an observational study. Int J Infect Dis. (2014)"/>
 <result pre="Clinical aspects and outcomes of 70 patients with middle east" exact="respiratory" post="syndrome coronavirus infection: a single-center experience in Saudi Arabia."/>
 <result pre="aspects and outcomes of 70 patients with middle east respiratory" exact="syndrome" post="coronavirus infection: a single-center experience in Saudi Arabia. Int"/>
 <result pre="demographic, and clinical characteristics of 47 cases of middle east" exact="respiratory" post="syndrome coronavirus disease from Saudi Arabia: a descriptive study."/>
 <result pre="and clinical characteristics of 47 cases of middle east respiratory" exact="syndrome" post="coronavirus disease from Saudi Arabia: a descriptive study. Lancet"/>
 <result pre="characteristics of 47 cases of middle east respiratory syndrome coronavirus" exact="disease" post="from Saudi Arabia: a descriptive study. Lancet Infect Dis."/>
 <result pre="Dis. (2013) 13:752–61. 10.1016/S1473-3099(13)70204-423891402 59.MemishZAZumlaAIAl-HakeemRFAl-RabeeahAAStephensGM. Family cluster of middle east" exact="respiratory" post="syndrome coronavirus infections. N Engl J Med. (2013) 368:2487–94."/>
 <result pre="(2013) 13:752–61. 10.1016/S1473-3099(13)70204-423891402 59.MemishZAZumlaAIAl-HakeemRFAl-RabeeahAAStephensGM. Family cluster of middle east respiratory" exact="syndrome" post="coronavirus infections. N Engl J Med. (2013) 368:2487–94. 10.1056/NEJMoa130372923718156"/>
 <result pre="61.https://www.who.int/influenza/surveillance_monitoring/updates/latest_update_GIP_surveillance/en/ 62.McCullersJA. Effect of antiviral treatment on the outcome of" exact="secondary" post="bacterial pneumonia after influenza. J Infect Dis. (2004) 190:519–26."/>
 <result pre="62.McCullersJA. Effect of antiviral treatment on the outcome of secondary" exact="bacterial pneumonia" post="after influenza. J Infect Dis. (2004) 190:519–26. 10.1086/42152515243927 63.collab:"/>
 <result pre="Effect of antiviral treatment on the outcome of secondary bacterial" exact="pneumonia" post="after influenza. J Infect Dis. (2004) 190:519–26. 10.1086/42152515243927 63.collab:"/>
 <result pre="influenza. J Infect Dis. (2004) 190:519–26. 10.1086/42152515243927 63.collab: Center for" exact="Disease" post="Control and Prevention (CDC) (2012) Available online at: https://www.cdc.gov/flu/spotlights/pandemic-global-estimates.htm"/>
 <result pre="Impact of antibacterials on subsequent resistance and clinical outcomes in" exact="adult" post="patients with viral pneumonia: an opportunity for stewardship. Critical"/>
 <result pre="on subsequent resistance and clinical outcomes in adult patients with" exact="viral" post="pneumonia: an opportunity for stewardship. Critical Care. (2015) 19:404."/>
 <result pre="stewardship. Critical Care. (2015) 19:404. 10.1186/s13054-015-1120-526577540 68.Abelenda-AlonsoGRombautsAGudiolCMeijeYOrtegaLClementeMet al.. Influenza and" exact="bacterial" post="coinfection in adults with community-acquired pneumonia admitted to conventional"/>
 <result pre="68.Abelenda-AlonsoGRombautsAGudiolCMeijeYOrtegaLClementeMet al.. Influenza and bacterial coinfection in adults with community-acquired" exact="pneumonia" post="admitted to conventional wards: risk factors, clinical features, and"/>
 <result pre="and immunohistochemical findings of 20 autopsy cases with (2009). H1N1" exact="virus infection." post="Modern Pathol. (2012) 25:1–3. 10.1038/modpathol.2011.18021874012 72.Perez-PadillaRDe La Rosa-ZamboniDPonce de"/>
 <result pre="Pathol. (2012) 25:1–3. 10.1038/modpathol.2011.18021874012 72.Perez-PadillaRDe La Rosa-ZamboniDPonce de LeonSHernandezMQuiñones-FalconiFBautistaEet al.." exact="Pneumonia" post="and respiratory failure from swine-origin influenza A (H1N1) in"/>
 <result pre="25:1–3. 10.1038/modpathol.2011.18021874012 72.Perez-PadillaRDe La Rosa-ZamboniDPonce de LeonSHernandezMQuiñones-FalconiFBautistaEet al.. Pneumonia and" exact="respiratory" post="failure from swine-origin influenza A (H1N1) in Mexico. N"/>
 <result pre="future. Front Microbiol. (2017) 8:981. 10.3389/fmicb.2017.0098128663740 81.CisekAADabrowskaIGregorczykKPWyzewskiZ. Phage therapy in" exact="bacterial infections" post="treatment: one hundred years after the discovery of bacteriophages."/>
 <result pre="Front Microbiol. (2017) 8:981. 10.3389/fmicb.2017.0098128663740 81.CisekAADabrowskaIGregorczykKPWyzewskiZ. Phage therapy in bacterial" exact="infections" post="treatment: one hundred years after the discovery of bacteriophages."/>
 <result pre="phage therapy. Infect Microb Dis. (2019) 1:34–42. 10.1097/IM9.0000000000000013 83.ManoharPLohBAthiraSNachimuthuRHuaXWelburnSCet al.." exact="Secondary" post="bacterial infections during pulmonary viral disease: phage therapeutics as"/>
 <result pre="therapy. Infect Microb Dis. (2019) 1:34–42. 10.1097/IM9.0000000000000013 83.ManoharPLohBAthiraSNachimuthuRHuaXWelburnSCet al.. Secondary" exact="bacterial infections" post="during pulmonary viral disease: phage therapeutics as alternatives to"/>
 <result pre="Infect Microb Dis. (2019) 1:34–42. 10.1097/IM9.0000000000000013 83.ManoharPLohBAthiraSNachimuthuRHuaXWelburnSCet al.. Secondary bacterial" exact="infections" post="during pulmonary viral disease: phage therapeutics as alternatives to"/>
 <result pre="Dis. (2019) 1:34–42. 10.1097/IM9.0000000000000013 83.ManoharPLohBAthiraSNachimuthuRHuaXWelburnSCet al.. Secondary bacterial infections during" exact="pulmonary" post="viral disease: phage therapeutics as alternatives to antibiotics?Front Microbiol."/>
 <result pre="(2019) 1:34–42. 10.1097/IM9.0000000000000013 83.ManoharPLohBAthiraSNachimuthuRHuaXWelburnSCet al.. Secondary bacterial infections during pulmonary" exact="viral" post="disease: phage therapeutics as alternatives to antibiotics?Front Microbiol. (2020)"/>
 <result pre="antibiotics?Front Microbiol. (2020) 11:1434. 10.3389/fmicb.2020.0143432733404 84.JohnsonBKAbramovitchRB. Small molecules that sabotage" exact="bacterial" post="virulence. Trends Pharmacol Sci. (2017) 38:339–62. 10.1016/j.tips.2017.01.00428209403 85.StarkeyMLepineFMauraDBandyopadhayaALesicBHeJet al.."/>
 <result pre="85.StarkeyMLepineFMauraDBandyopadhayaALesicBHeJet al.. Identification of anti-virulence compounds that disrupt quorum-sensing regulated" exact="acute" post="and persistent pathogenicity. PLoS Pathog. (2014) 10:e1004321. 10.1371/journal.ppat.100432125144274"/>
</results>
